File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.canlet.2008.08.018
- Scopus: eid_2-s2.0-57349106607
- PMID: 18824293
- WOS: WOS:000262582100003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
Title | Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Keywords | Chemoresistance Chemosensitivity HCC mTOR p53 RAD001 | ||||||
Issue Date | 2009 | ||||||
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet | ||||||
Citation | Cancer Letters, 2009, v. 273 n. 2, p. 201-209 How to Cite? | ||||||
Abstract | The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. © 2008 Elsevier Ireland Ltd. All rights reserved. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/59161 | ||||||
ISSN | 2023 Impact Factor: 9.1 2023 SCImago Journal Rankings: 2.595 | ||||||
ISI Accession Number ID |
Funding Information: The study was supported by the Seed Funding Program for Basic Research 2006 and Sun Chieh Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery of the University of Hong Kong. | ||||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tam, KH | en_HK |
dc.contributor.author | Yang, ZF | en_HK |
dc.contributor.author | Lau, CK | en_HK |
dc.contributor.author | Lam, CT | en_HK |
dc.contributor.author | Pang, RWC | en_HK |
dc.contributor.author | Poon, RTP | en_HK |
dc.date.accessioned | 2010-05-31T03:44:03Z | - |
dc.date.available | 2010-05-31T03:44:03Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Cancer Letters, 2009, v. 273 n. 2, p. 201-209 | en_HK |
dc.identifier.issn | 0304-3835 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/59161 | - |
dc.description.abstract | The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. © 2008 Elsevier Ireland Ltd. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet | en_HK |
dc.relation.ispartof | Cancer Letters | en_HK |
dc.rights | Cancer Letters. Copyright © Elsevier Ireland Ltd. | en_HK |
dc.subject | Chemoresistance | en_HK |
dc.subject | Chemosensitivity | en_HK |
dc.subject | HCC | en_HK |
dc.subject | mTOR | en_HK |
dc.subject | p53 | en_HK |
dc.subject | RAD001 | en_HK |
dc.title | Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0304-3835&volume=273&issue=2&spage=201&epage=209&date=2009&atitle=Inhibition+of+mTOR+enhances+chemosensitivity+in+hepatocellular+carcinoma | en_HK |
dc.identifier.email | Pang, RWC: robertap@hkucc.hku.hk | en_HK |
dc.identifier.email | Poon, RTP: poontp@hkucc.hku.hk | en_HK |
dc.identifier.authority | Pang, RWC=rp00274 | en_HK |
dc.identifier.authority | Poon, RTP=rp00446 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.canlet.2008.08.018 | en_HK |
dc.identifier.pmid | 18824293 | - |
dc.identifier.scopus | eid_2-s2.0-57349106607 | en_HK |
dc.identifier.hkuros | 154431 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-57349106607&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 273 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 201 | en_HK |
dc.identifier.epage | 209 | en_HK |
dc.identifier.isi | WOS:000262582100003 | - |
dc.publisher.place | Ireland | en_HK |
dc.identifier.scopusauthorid | Tam, KH=7201692833 | en_HK |
dc.identifier.scopusauthorid | Yang, ZF=39863860200 | en_HK |
dc.identifier.scopusauthorid | Lau, CK=7401968442 | en_HK |
dc.identifier.scopusauthorid | Lam, CT=7402989860 | en_HK |
dc.identifier.scopusauthorid | Pang, RWC=7004376659 | en_HK |
dc.identifier.scopusauthorid | Poon, RTP=7103097223 | en_HK |
dc.identifier.issnl | 0304-3835 | - |